Market Access News | pharmaphorum

News

Merck & Co signs biosimilars deal for US veterans

Merck & Co has signed a deal with the US Department of Veterans Affairs (VA) for its inflammatory diseases biosimilar, Renflexis, so that veterans’ care can be improved.

News

Denmark funds Vertex's CF drug Orkambi, UK talks deadlocked

As uncertainty hangs over the availability of Vertex’s cystic fibrosis drug in England, the company has signed an agreement that gives Danish patients access to Orkambi.

News

Lilly pushes into migraine market as Emgality approved in US

The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.

News

CSL Behring lung drug would cost NHS £8m per patient, says N...

NICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it would cost a massive £8 million to give a patient a ye

News

Patients call for end to CF drug price row at key meeting

Representatives of NHS England and cystic fibrosis drug company Vertex are to meet on Thursday to try and resolve a two-year impasse over access to life-changing medications.

News

Novartis, Bayer consider appeal as court says Avastin can be...

England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs

Merck & Co signs biosimilars deal for US veterans

Denmark funds Vertex's CF drug Orkambi, UK talks deadlocked

Lilly pushes into migraine market as Emgality approved in US

CSL Behring lung drug would cost NHS £8m per patient, says N...

Patients call for end to CF drug price row at key meeting

Novartis, Bayer consider appeal as court says Avastin can be...

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks